CVRx (CVRX) Competitors

CVRx (NASDAQ:CVRX) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Does the media favor CVRX or BVS?

In the previous week, Bioventus had 1 more articles in the media than CVRx. MarketBeat recorded 4 mentions for Bioventus and 3 mentions for CVRx. Bioventus' average media sentiment score of 1.08 beat CVRx's score of 0.96 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in CVRX or BVS?

75.3% of CVRx shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 18.9% of CVRx shares are owned by insiders. Comparatively, 32.9% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is CVRX or BVS more profitable?

Bioventus has a net margin of -7.11% compared to CVRx's net margin of -116.91%. Bioventus' return on equity of 15.61% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-116.91%	-93.06%	-51.78%
Bioventus	-7.11%	15.61%	4.01%

Do analysts recommend CVRX or BVS?

CVRx currently has a consensus price target of $16.83, suggesting a potential upside of 124.74%. Bioventus has a consensus price target of $15.00, suggesting a potential upside of 103.03%. Given CVRx's stronger consensus rating and higher probable upside, research analysts clearly believe CVRx is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has higher earnings & valuation, CVRX or BVS?

CVRx has higher earnings, but lower revenue than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$51.29M	3.80	-$59.97M	-$2.69	-2.78
Bioventus	$573.28M	1.06	-$156.23M	-$0.51	-14.49

Which has more volatility and risk, CVRX or BVS?

CVRx has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Does the MarketBeat Community believe in CVRX or BVS?

CVRx received 4 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 74.47% of users gave CVRx an outperform vote while only 63.27% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
CVRx	Outperform Votes 35 74.47%	Underperform Votes 12 25.53%
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%

Summary

CVRx beats Bioventus on 10 of the 18 factors compared between the two stocks.